

Review Article

Isocitrate dehydrogenase gene variants in cancer and their clinical significance

Thomas Cadoux-Hudson, Christopher J. Schofield and  James S.O. McCullagh

Chemistry Research Laboratory, Department of Chemistry and the Ineos Institute for Antimicrobial Research, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.

Correspondence: James S.O. McCullagh (james.mccullagh@chem.ox.ac.uk)



Human *isocitrate dehydrogenase (IDH)* genes encode for the IDH1, 2 & 3 isoenzymes which catalyse the formation of 2-oxoglutarate from isocitrate and are essential for normal mammalian metabolism. Although mutations in these genes in cancer were long thought to lead to a ‘loss of function’, combined genomic and metabolomic studies led to the discovery that a common *IDH 1* mutation, present in low-grade glioma and acute myeloid leukaemia (AML), yields a variant (R132H) with a striking change of function leading to the production of (2*R*)-hydroxyglutarate (2HG) which consequently accumulates in large quantities both within and outside cells. Elevated 2HG is proposed to promote tumorigenesis, although the precise mechanism by which it does this remains uncertain. Inhibitors of R132H IDH1, and other subsequently identified cancer-linked 2HG producing IDH variants, are approved for clinical use in the treatment of chemotherapy-resistant AML, though resistance enabled by additional substitutions has emerged. In this review, we provide a current overview of cancer linked *IDH* mutations focussing on their distribution in different cancer types, the effects of substitution mutations on enzyme activity, the mode of action of recently developed inhibitors, and their relationship with emerging resistance-mediating double mutations.

Introduction

Studies on the roles of altered genetics and metabolism have a long history in cancer research; famously, Otto Warburg [1] demonstrated increased lactate production in cancer cells grown in normoxic conditions. The exact mechanisms orchestrating the change towards glycolytic metabolism in some cancer cells have, however, remained elusive. Research in 2006 analysing cancer-associated mutations revealed an *isocitrate dehydrogenase 1 (IDH 1)* mutation in a colorectal cancer, leading to the R132C IDH1 variant [2]. Analysis of primary brain tumours revealed a heterogeneous G395A mutation in *IDH1* (R132H) in 5 of 22 glioblastoma (GBM) patients with a further 3 GBM patients having the R132S variant [3]. Interestingly, the *IDH1* mutation in primary brain tumours is linked to better survival [3]. The heterogeneous nature of the G395A mutation, likely resulting in heterodimeric IDH proteins, suggests that rather than a simple loss of function, the IDH1 variants may catalyse a neomorphic reaction, i.e. one not catalysed by homodimeric wild-type IDH1 (wtIDH1). Indeed, in a breakthrough study the R132H IDH1 variant was shown to enhance the production of the endogenous metabolite 2-hydroxyglutarate (2HG), which was observed to accumulate to concentrations in the range 3–35 $\mu\text{M/g}$ of tumour in patient R132H IDH1 glioma tissues, whilst wild-type IDH1 tumours manifested over 100-fold less 2HG [4]. U87MG glioblastoma cells transfected with a pCMV6 plasmid encoding for R132H IDH1 also accumulated 2HG. The carbon atoms of 2HG were shown to derive from glutamate using ^{13}C -tracer experiments [4].

There are 3 forms of homodimeric IDH in mammalian cells. IDH1/2 (EC code: 1.1.1.42 and IDH3 (EC code: 1.1.1.41). Two of these (IDH1/2) catalyse the same metabolic reaction, namely the reversible conversion of isocitrate to alpha-ketoglutarate (α -KG) or 2-oxoglutarate (2OG), and NADP⁺ to NADPH (Figure 1). IDH1 localises in the cytoplasm and peroxisomes, whereas IDH2 and IDH3 localise in mitochondria. IDH1 and IDH2 are important for their contribution in maintaining local and

Received: 4 August 2021
 Revised: 13 October 2021
 Accepted: 18 October 2021

Version of Record published:
 2 December 2021




Figure 1. Reactions catalysed by wild-type IDH and the gain of function IDH1/2 variants.

Note, IDH1 and IDH2 catalyse the reversible NADP^+ dependent production of 2OG and CO_2 , whereas IDH3 employs NAD^+ in an apparently irreversible reaction. No evidence for reversibility of IDH1/2 variant-catalysed production of 2HG has been reported.

cellular NADPH levels and the cellular redox balance. IDH3 also converts isocitrate to 2OG in conjunction with conversion of NAD^+ to NADH . The IDH3 reaction is an essential and a rate-limiting step in the mitochondrial tricarboxylic acid (TCA) cycle (Figure 2). The IDH1/2, but not IDH3, reactions are reversible, with the direction apparently being determined by substrate/product concentrations [5].

Although the IDH enzymes have long been studied, aspects of their regulation are poorly understood. For example, there is evidence that wtIDH1 binds mRNA in embryonic stem cells (ESC), in particular guanine/adenine (GA) and adenine/uracil (AU) rich single-stranded mRNA, but not double-stranded RNA or DNA [6].




Figure 2. Normal functions of IDH1, IDH2 and IDH3 (green boxes) and 2HG production by variant IDH1/2 (orange boxes).

IDH1 is localised in the cytosol and peroxisome; IDH2 and IDH3 localise to the mitochondrial matrix. IDH1/2 reversibly oxidise isocitrate to 2OG and CO_2 , producing NADPH . IDH3 is part of the TCA cycle and oxidises isocitrate to 2OG, producing NADH . Normal functions of IDH1, IDH2 and IDH3 (green boxes). Substrates and reaction products of normal IDH function (blue boxes). 2HG production by variant IDH1/2 (orange boxes). Solid arrows denote direct reactions, dashed arrows denote ‘promiscuous’ pathways. Note, (2R)-HG is biosynthesised by the metabolism of 5-hydroxy-(2S)-lysine, by the hydroxy acid oxoacid *trans*-hydrogenase (HOT) and phosphoglycerate dehydrogenase (PHGDH) (yellow boxes). (2S)-HG is biosynthesised by reactions catalysed by mitochondrial malate dehydrogenase 1 and 2 (MDH1/2) and lactate dehydrogenase A (LDHA). (R)-2HG and (S)-2HG are oxidised to 2OG by (R)-2HG and (S)-2HG dehydrogenases ((R)- or (S)-2-HGDH) (green) in reactions where an acceptor (R) is reduced (RH_2). Abbreviations: 2OG (2-oxoglutarate), citrate transport protein (CTP), AlkB homologues (AlkBHs).

A significant decrease in RNA binding is reported for the R132H IDH1 variant. The function of RNA binding to IDH1 is unknown, and may be involved in *IDH1* regulation.

The IDH isoenzymes all catalyse the production of 2OG, which can also be obtained from the diet and transported into cells [7,8]. IDH1/2 catalysed reductive carboxylation can also occur leading to the formation of isocitrate and subsequently citrate from 2OG, a process which links 2OG with lipid metabolism via isocitrate production [9].

2OG is involved in a variety of metabolic processes, including the biosynthesis of amino acids and as a co-substrate for the large family of 2OG/Fe (II)-dependent dioxygenases, of which there are 60–70 in humans. The 2OG dioxygenases have diverse roles that include collagen biosynthesis, lipid metabolism, transcription, DNA repair, and hypoxia signalling [10–12]. It has been proposed that elevated 2HG levels in IDH mutant-bearing cells leads to inhibition of 2OG oxygenases involved in chromatin modification in accordance with a role for elevated 2HG in tumorigenesis [13]. It is also possible that non-enzymatic or promiscuous oxidation of 2HG to 2OG may occur with an apparently paradoxical increase in activity of some dioxygenases [14].

2HG is produced at low levels in normal (wtIDH) mammalian cells under physiological conditions by a number of enzymes (Figure 2), at least in some cases by apparently ‘promiscuous’ activities [15]. Such enzymes include phosphoglycerate dehydrogenase [16] and hydroxyacid-oxoacid transferase (HOT), both part of γ -hydroxybutyrate metabolism [17], which can produce (2R)-HG. The promiscuous reactions of lactate dehydrogenase (LD), pyruvate dehydrogenase (PD) and fumarate hydratase (FH), produce (2S)-HG [18] under acidic conditions, which is often observed in tumour and stem cells [19].

Under normal cellular conditions, cytoplasmic 2HG levels are kept low by the citrate transporter protein (CTP or CIC), which is encoded for by the *SLC25A1* gene, and which transports (2R)- and (2S)-2HG into mitochondria, where (2R) and (2S) enantio-selective NAD⁺-dependent 2-hydroxyglutarate dehydrogenases (2-HGDH) convert them into 2OG [20]. Inborn errors of metabolism arising from mutations to the genes for either of the 2-HGDH isoenzymes or CTP, can lead to accumulation of either 2HG enantiomer resulting in 2-hydroxyglutarate aciduria, with a possible increase in tumour progression [21] with associated poor patient outcomes. [22] Mosaic *IDH* mutations are characteristic of Ollier and Maffucci syndrome, which manifests raised tissue 2HG and osteoid tumours, and of specific IDH mutations, which are associated with increased risk of glioma formation [23].

Most mutations, occurring via non-synonymous single nucleotide polymorphism (NS-SNP) and other nucleotide derangements, resulting in protein variants associated with cancer, are believed to result in a ‘loss of function’ (LOF; hyper- or hypo-morphic) [24]. In the case of metabolic enzymes, loss of function is normally manifest in a failure of catalysis, e.g. to produce a specific metabolite often leading to accumulation of precursors. ‘Gain of function’ (GOF) mutations can lead to the relevant enzyme producing an alternative metabolite; in most cases, GOF is likely more difficult to identify than LOF, but the available evidence is that GOF is much rarer than LOF. *IDH* mutations have therefore attracted considerable interest because of the clear consequential GOF with the implication that the novel production and accumulation of 2HG supports tumorigenesis. The precise mechanism(s) by which elevated 2HG promotes cancer emergence and progression remain unclear. The study of elevated 2HG on cancer cell function has been extensive, for example investigation of gene expression/genomics [25], DNA repair [26], epigenetics [13], lipidomics [27], and small-molecule metabolism [28].

The canonical *IDH1* ϵ -2 mutations (e.g. resulting in IDH1R132 and IDH2R172) are found close to intron/exon interfaces (Table 1), which typically have been found to have a lower incidence of mutation when compared with more central exon components [29].

Table 1 Chromosomal locations of Human *IDH1&2*, with common codon changes, exon, and proximity to the intron/exon boundary

	IDH1 R100	IDH1 R132	IDH2 R140	IDH2 R172
Codon	CGG	CGT	No data available?	AGG
Chromosome	2q34	2q34	15q26.1	15q26.1
Exon	4	4	4	4
Exon/Intron interface	No	Yes	Yes	Yes
SNP reference NCBI gene	rs276606870	rs121913500	Rs121913502	rs121913503

SNP, single nucleotide polymorphism; NCBI, National Center for Biotechnology Information.

Table 2 Common and rare codons with nucleotide *substitutions* corresponding to residues R132 (IDH1), R172 (IDH2), and R140 (IDH2)

Cancer type	IDH1 R132 (CGT)		IDH2 R172 (AGG)		IDH2 R140 (CGG)		Reference
	Common	Rare	Common	Rare	Common	Rare	
Glioma	CAT (H)	TGT(C), AGT(S), GGT (G), CTT(L), GTT(V)	-	AAG(K), GGG(G), ATG(M), TGG(W)	-	TGG(W)	[3,30–33]
Chondrosarcoma	TGT(C)	GGT(G), CAT(H), CTT (L), AGT(S)	S	AAG(K), GGG(G)	-	CAG(Q), TGG(W)	[34–46]
Acute myeloid leukaemia	CAT(H), TGT (C)	AGT(S)	-	-	(CAG)Q	K, TGG(W), CTG(L)	[37–41]
Intrahepatic cholangiocarcinoma	C	AGT(S), CTT(L), GGT (G)	AAG(K), TGG (W)	GGG(G), ATG(M), AAT(N)*	-	-	[42,43]
Angioimmunoblastic T-cell lymphoma	-	-	AAG(K),	GGG(G) TAT(T)*	-	GGG(G)	[44]
Sinonasal undifferentiated carcinoma	-	-	AGT(S)*	TAI(T)*, ATG(M), GGG(G),	-	-	[45,46]
Solid papillary carcinoma with reverse polarity P	-	-	GGG(G) AGT(S), TAT(T)	-	-	-	[47,48]

Encoded amino acid residues are in parentheses.

Chromosomal translocation of a gene is the most common genome abnormality associated with cancer and can alter expression levels and function [85]. Oligodendroglioma, a primary brain tumour, is commonly associated with *IDH* (1 more commonly than 2) and 1p/19q codeletion. Cancer related chromosomal translocations/deletions involving Chromosome region 2q34 (location of *IDH1*) and Chromosome region 15q26.1 (location of *IDH2*) are relatively rare. Chromosome deletions, associated with Myelodysplasia, are reported for *IDH2* Chr 15q26.1 [86], but none have been reported for *IDH1* Chr 2q34. *IDH1* or 2 deletion would be expected to be associated with loss of *IDH* function causing perturbed metabolism, due to a reduction in cellular 2OG and/or NADPH, with a possible decrease in the efficiency of DNA damage repair and consequently increased risk of cancer.

Clinical incidence of *IDH1*, *IDH2* and *IDH3* variants

The distribution of *IDH* mutations in human pathology varies with the tissue of origin (Table 2). Low grade glioma has a higher incidence of *IDH 1* compared with *IDH2* mutations, of which the *IDH* R132H mutation dominates (R132H (CAT) 92.7%, R132C (TGT) 3.6%, R132S (AGT) 1.8%, R132G (GGT) 0.9%, R132L (CTT) 0.9%, R132V (GTT) 0.5%) [30]. Anaplastic R132H glioma typically present at a younger age; a trend that is not significant in rarer R132H glioma cell types. In glioma, non-canonical (i.e. not *IDH1* R132H or *IDH2* R170C) *IDH1* variants have different clinical characteristics and tend to arise in different locations in the brain compared with the canonical variants [31]. There appears to be an even distribution of *IDH1*&2 mutations at low levels (less than 10%) in human cancers apart from high levels (80%) of *IDH1* mutations in human low grade glioma. *IDH2* mutations are more common in Acute myeloid and B-cell acute lymphoblastic leukaemia (20–33%), and cartilaginous bone tumours such as giant cell tumour of bone/osteoclastoma (80%) and osteosarcoma (28%). Within breast cancer (*IDH1* mutation at 0.2%) the exception is the solid papillary carcinoma with reverse polarity (*IDH2* >77%) (Table 3). In AML, *IDH2* mutations are more common than those of *IDH1* (Table 3) [38]. Interestingly, in AML, *IDH2* mutations and 2OG oxygenase Ten/Eleven Translocation enzyme (*TET2*) mutations (usually LOF) appear to be mutually exclusive, but the reasons for this are unknown [41]. Intrahepatic cholangiosarcoma have a high incidence of *IDH1* mutations as do chondrosarcomas [42], with giant cell tumour/osteoclastoma dominated by *IDH2* mutations [68]. *IDH* mutations are generally rare in some common cancers (breast, prostate and gastric), apart from some rare sub-types such as Breast Solid Papillary carcinoma with reverse polarity, where 77% of cases have *IDH2* mutations [47].

IDH wild-type and variant enzyme kinetics

wt*IDH1* kinetics have been studied for some time, with more recent analysis on recombinant wt*IDH* and its variants [87,88]. wt*IDH2* and wt*IDH3* have been relatively little studied from a kinetic perspective, at least

Table 3 Reported occurrence frequency (%) of the canonical *IDH1* and *IDH2* variants in cancers and benign tumours

Part 1 of 2

Cancer type	Reported occurrence (%)			Source
	mtIDH1 (R132)	mtIDH2 (R172 or R140)	Non-canonical mtIDH1 or 2	
Central nervous system neoplasm				
Low grade glioma (grade II-III)	>70	5	0.3–2.3	[30–33]
Secondary GBM (grade IV)	55–88	3.4	-	[49]
Primary GBM (grade IV)	5–14	0.5	-	[50]
Myeloid and lymphoid neoplasms				
Acute myeloid leukaemia	6–13	8–20	0.6	[37–41,51,52,122–124]
B-cell acute lymphoblastic leukaemia	1.7	-	-	[53]
Angioimmunoblastic T-cell lymphoma	-	20–33	-	[44]
Peripheral T-cell lymphoma	-	<5	-	[54]
Myelodysplastic syndrome	<4	<4	-	[52]
Myeloproliferative neoplasm — chronic- or fibrotic-phase	<3	<1.5	-	[55]
Myeloproliferative neoplasm — blast-phase	5–12	2–9	-	[56]
Paediatric acute myeloid and lymphoblastic leukaemia	<1.5	<2.5	-	[57,58]
Bile duct neoplasms				
Intrahepatic cholangiocarcinoma	6.5–32	1–9	0.3	[42,43,59–62]
Extrahepatic cholangiocarcinoma/Clear cell extrahepatic cholangiocarcinoma	0–10	<4	-	[63]
Cartilage and bone neoplasms				
Chondrosarcoma	12–54	5–16	-	[36,64–67]
Giant-cell tumour of the bone/Osteoclastoma	-	80	25	[68]
Osteosarcoma	-	28	-	[69]
ESFT	3.3	3.3	-	[70]
Ollier disease and Mafucci syndrome related neoplasms				
Ollier and Mafucci related enchondroma and chondrosarcomas	>80	3	-	[71,72]
Mafucci syndrome related haemangioma	1 reported case	-	-	[72]
Mafucci syndrome related spindle cell haemangioma	70	-	-	[71]
Other neoplasms				
Breast cancer (other)	0.2	-	-	[73]
Solid papillary carcinoma with reverse polarity — rare breast cancer subtype	-	>77	-	[38,47]
Gastric adenocarcinoma	2.7	-	-	[74]
Irritable bowel syndrome-associated intestinal adenocarcinoma	13	-	-	[75]
Melanoma metastasis	1.3	-	-	[76]
Non-small cell lung cancer	0.6	0.4	-	[77]
Paraganglioma	1.5	-	-	[78]
Prostate cancer	0.3–2.7	-	-	[67,79]
Sinonasal undifferentiated carcinoma	-	35–80	-	[80]

Continued

Downloaded from http://port.silverchair.com/biochemstrans/article-pdf/49/6/2561/928203/bst-2021-1-0277.c.pdf by guest on 28 September 2023

Table 3 Reported occurrence frequency (%) of the canonical *IDH1* and *IDH2* variants in cancers and benign tumours

Part 2 of 2

Cancer type	Reported occurrence (%)			Source
	wtIDH1 (R132)	mtIDH2 (R172 or R140)	Non-canonical mtIDH1 or 2	
Spindle cell haemangioma	28	7.1	3.6	[71,81]
Thyroid cancer	-	-	8–16	[82,83]
Wilms tumour	-	-	10	[84]

using isolated recombinant enzymes. Some (at least) of the clinical *IDH1* variants, including R132H, catalyse isocitrate oxidation, though like the variant catalysed reduction in 2OG to 2HG, this is a much lower rate than wtIDH1, as judged by k_{cat}/K_M values [19]. R132H *IDH1* has a high 2OG K_M of >500 μM and the k_{cat}/K_M of R132H *IDH1* for 2OG reduction is >1000 times lower than that of wtIDH1 for isocitrate oxidation. However, this is only slightly higher than that for R132H *IDH1* catalysed isocitrate oxidation. The forward reaction of wtIDH1 requires Mg^{2+} (Mn^{2+} also works, but is less likely to be biologically relevant) and is inhibited by Ca^{2+} [87]. Evidence from *in vivo* studies suggests that there is sufficient free $\text{Mg}^{2+}/\text{Mg}^{2+}$ homeostasis to enable efficient wtIDH catalysis [89,90] and levels of free Ca^{2+} in cells are kept low and presumably are at insufficient levels to cause *IDH1/2* inhibition, though localised effects cannot be ruled out [91]. wtIDH1 (and likely variant) enzyme kinetics are complicated. wtIDH1, like all studied clinically relevant variants, is predominantly dimeric in solution; its conformation interconverts between open and closed forms with its turnover number decreasing at high enzyme concentrations [87,88]. At least in purified recombinant form, human wtIDH1 co-purifies with two molecules of NADPH; however, its catalytically active dimeric form is reported to have half-site reactivity [87,88]. Binding of Mg^{2+} and isocitrate to its active site promotes release of one molecule of NADPH to provide a dimer with a single bound molecule of NADPH [88].

The forward wtIDH1 reaction, i.e. of isocitrate to 2OG and CO_2 , is usually studied at neutral pH, with the reverse reductive decarboxylation reaction being preferred at acidic pH [19]. The k_{cat} for wtIDH catalysed isocitrate oxidation increases from $20.0 \pm 0.4 \text{ s}^{-1}$ to $38.3 \pm 0.9 \text{ s}^{-1}$ as the pH increases from pH 6.2 to pH 8 with maximal efficiency about pH 7.5, $(1.4 \pm 0.1) \times 10^3 \text{ mM}^{-1} \text{ s}^{-1}$ [92]. These observations suggest that cellular pH may influence wtIDH/*IDH* variant catalysis.

Modulation of the ionisation state of Asp273 is proposed to be involved in the pH-mediated regulation of wtIDH; substitutions of Asp273 reduce catalytic efficiency and cause loss of pH regulatory effects [92]. The intracellular pH (pHi) has been measured as 7.01 ± 0.2 in normal brain *in vivo* by ^{31}P Magnetic resonance spectroscopy (MRS) but is more basic (pHi 7.18) in glioma [32,93]. Combined, these observations suggest that, at least in human glioma with respect to pHi, the forward reaction of wtIDH1 is likely preferred over the reverse reaction.

Inhibition of 2HG-producing *IDH1/2* variants in cancer

As reviewed elsewhere, medicinal chemistry efforts focused on *IDH1/2* variants have produced inhibitors that have been approved for clinical use or which are currently in development [94]. Interestingly, despite substantial structural variations and (in many cases) their selectivity for R132H (and/or other variants) over wtIDH1, most reported potent R132H *IDH1* inhibitors, e.g. BAY-1436032 [95], GSK321 [96] *IDH305* [97], and ML309 [98] (IC_{50} all <100 nM) do not appear to bind in the same active site location as do isocitrate / Mg^{2+} , which is where most clinically relevant *IDH1/2* substitutions occur (as evidenced by crystallographic analyses) [99]. Instead, although kinetic analyses with the inhibitors can manifest apparent substrate/ Mg^{2+} competition, they bind at the dimer interface, i.e. they are allosteric inhibitors [96]. The observations of allosteric inhibition may in part reflect as yet unidentified allosteric mechanisms of *IDH1/2* regulation *in vivo*. Further detailed studies on molecular aspects of the mechanisms of inhibition and *IDH* catalysis may aid in the development of improved *IDH* targeted therapies.

The development of *IDH1/2* variant inhibitors has been driven by the hypothesis that reducing levels of the ‘oncometabolite’ 2HG may reduce tumour progression, halt malignant transformation, and/or improve patient survival. Several clinical trials have been performed and others are underway [100–111]. Treatment with first-generation *IDH* variant inhibitors results in a reduction in tissue 2HG levels [112]. However, it has been noted

that inhibitor treatment did not slow tumour growth in some cases, e.g. in the case of some glioma and chondrosarcoma model cell lines [113]

The use of IDH variant inhibitors in therapy-resistant AML has shown improved survival [114], but has revealed variable impacts on plasma 2HG concentrations [115]. The successful reduction in plasma 2HG levels has been associated with ‘differentiation syndrome’ whereby immature macrophages mature and differentiate, releasing inflammatory compounds and producing a septic shock-type clinical outcome [116].

Inhibitor resistant *IDH* ‘double’ mutations have been reported in association with inhibitor treatment, with consequent re-emergence of high 2HG plasma levels [117]. *IDH2* double or secondary mutations were reported to have either: (i) been present before inhibitor therapy, but present only in a small population and hence were not detected, or (ii) developed during treatment *in trans* to the canonical *IDH1* R140Q gene resulting in double R140Q/Q316E and/or R140Q/I319M variants. [117]. Cell culture studies in murine Ba/F3 haemopoietic cells indicate that the ‘secondary’ mutations do not alter the efficiency of 2HG production, but interfere with allosteric inhibitor binding [117]. Isoform switching, whereby the mutation sequence switches from one *IDH* isoform to another (e.g. *IDH1* to *IDH2*) has been observed after an initial response to a specific *IDH* inhibitor [118]. Thus, treatment with Ivosidenib, which is selective for inhibition of *IDH1* variants, can result in selection for an *IDH2* mutation with consequent production of 2HG, the *IDH2* variant responds to treatment with the *IDH2* variant-selective inhibitor Enasidenib [119]. *IDH* variant drug resistance is also known to be caused by mutations in genes other than those which encode the *IDHs*, such as for receptor tyrosine kinase (RTK) for example [114].

Perspectives

- *IDH* mutations are rare gain-of-function mutations that cause accumulation of high levels of intra- and extra-cellular 2-hydroxyglutarate, now considered an ‘oncometabolite’. Robust and selective inhibition of *IDH1/2* variants, resulting in reduced 2HG levels, has been demonstrated and is being explored as a new avenue in cancer therapy.
- Although there are proposed mechanisms for how 2HG acts as an ‘oncometabolite’, e.g. inhibition of chromatin modifying 2OG oxygenases by 2HG, further work is required to define and validate the proposed molecular links between *IDH* mutations and the processes of tumorigenesis leading to cancer and progression. Exploring the potential pro-oncogenic roles of *IDH1/2* variant-induced metabolic changes beyond elevated 2HG is of significant interest. The development of a molecular understanding of how changes in metabolism promotes cancer should help in the clinical deployment of *IDH* variant inhibitors, which have shown clear efficacy in reducing 2HG levels, but which have not always led to patient benefit.
- To circumvent the problems of emerging resistance due to doubly substituted *IDH* variants, the development of new generation *IDH* variant inhibitors, that inhibit not only the range of canonical *IDH1/2* variants with a single substitution but which also inhibit the double variants, is of interest [120]. The discovery of the gain-of-function *IDH1/2* variants raises therapeutic possibilities outside of *IDH* variant inhibition, e.g. the apparently important role of glutamine in *IDH* mutant tumours provides the potential for other therapeutic approaches, such as inhibition of glutaminase in combination with radiotherapy of astrocytoma as well as the possibility of combination therapies [121].

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Open Access

Open access for this article was enabled by the participation of University of Oxford in an all-inclusive *Read & Publish* pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.

Author Contributions

T.C.H. and J.M. conceived the focus of the review. T.C.H. researched the literature and wrote the manuscript with input from C.J.S. and J.M. C.J.S. and J.M. contributed sub-sections and all authors revised and edited the manuscript.

Acknowledgements

We thank Ingviid Hvinden from the McCullagh Group for her help with figures. C.J.S. thanks the Wellcome Trust and Cancer Research UK for funding. This research was funded in whole, or in part, by the Wellcome Trust [grant no. 106244/Z/14/Z]. For the purpose of open access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Abbreviations

AML, acute myeloid leukaemia; CTP, citrate transporter protein; GBM, glioblastoma; GOF, gain of function; HOT, hydroxyacid-oxoacid transferase; *IDH*, isocitrate dehydrogenase; LOF, loss of function; SNP, single nucleotide polymorphism; TCA, tricarboxylic acid.

References

- Warburg, O. (1956) On the origin of cancer cells. *Science* **123**, 309–314 <https://doi.org/10.1126/science.123.3191.309>
- Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D. et al. (2006) The consensus coding sequences of human breast and colorectal cancers. *Science* **314**, 268–274 <https://doi.org/10.1126/science.1133427>
- Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.H., Leary, R.J., Angenendt, P. et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. *Science* **321**, 1807–1812 <https://doi.org/10.1126/science.1164382>
- Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M. et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* **462**, 739–746 <https://doi.org/10.1038/nature08617>
- Leonardi, R., Subramanian, C., Jackowski, S. and Rock, C.O. (2012) Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. *J. Biol. Chem.* **287**, 14615–14620 <https://doi.org/10.1074/jbc.C112.353946>
- Liu, L., Li, T., Song, G., He, Q., Yin, Y., Lu, J.Y. et al. (2019) Insight into novel RNA-binding activities via large-scale analysis of lncRNA-bound proteome and IDH1-bound transcriptome. *Nucleic Acids Res.* **47**, 2244–2262 <https://doi.org/10.1093/nar/gkz032>
- Hou, Y., Wang, L., Ding, B., Liu, Y., Zhu, H., Liu, J. et al. (2011) Alpha-Ketoglutarate and intestinal function. *Front. Biosci.* **16**, 1186–1196 <https://doi.org/10.2741/3783>
- He, L., Xu, Z., Yao, K., Wu, G., Yin, Y., Nyachoti, C.M. et al. (2015) The physiological basis and nutritional function of alpha-ketoglutarate. *Curr. Protein Peptide Sci.* **16**, 576–581 <https://doi.org/10.2174/1389203716666150630140157>
- Bueno, M.J., Jimenez-Renard, V., Samino, S., Capellades, J., Junza, A., López-Rodríguez, M.L. et al. (2019) Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. *Nat. Commun.* **10**, 5011 <https://doi.org/10.1038/s41467-019-13028->
- Loenarz, C. and Schofield, C.J. (2008) Expanding chemical biology of 2-oxoglutarate oxygenases. *Nat. Chem. Biol.* **4**, 152–156 <https://doi.org/10.1038/nchembio0308-152>
- Iyer, L.M., Tahiliani, M., Rao, A. and Aravind, L. (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. *Cell Cycle* **8**, 1698–1710 <https://doi.org/10.4161/cc.8.11.8580>
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H. et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. *Cancer Cell* **19**, 17–30 <https://doi.org/10.1016/j.ccr.2010.12.014>
- Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R. et al. (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep.* **12**, 463–469 <https://doi.org/10.1038/embor.2011.43>
- Tarhonskaya, H., Rydzik, A.M., Leung, I.K., Loik, N.D., Chan, M.C., Kawamura, A. et al. (2014) Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. *Nat. Commun.* **5**, 3423 <https://doi.org/10.1038/ncomms4423>
- Ye, D., Guan, K.L. and Xiong, Y. (2018) Metabolism, activity, and targeting of D- and L-2-hydroxyglutarate. *Trends Cancer* **4**, 151–165 <https://doi.org/10.1016/j.trecan.2017.12.005>
- Fan, J., Teng, X., Mattaini, K.R., Looper, R.E. and Vander Heiden, H.G. (2015) Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. *ACS Chem. Biol.* **10**, 510–516 <https://doi.org/10.1021/cb500683c>
- Struys, E.A., Verhoeven, N.M., Ten Brink, H.J., Wickenhagen, W., Gibson, K.M. and Jakobs, C. (2005) Kinetic characterization of human hydroxy-oxoacid transhydrogenase: relevance to D-2-hydroxyglutarate and gamma-hydroxy butyric acidurias. *J. Inher. Metab. Dis.* **28**, 921–930 <https://doi.org/10.1007/s10545-005-0114-x>
- Intlekofer, A.M., Dematteo, R.G., Venneti, S., Finley, L.W., Lu, C., Judkins, A.R. et al. (2015) Hypoxia induces production of L-2-hydroxyglutarate. *Cell Metab.* **22**, 304–311 <https://doi.org/10.1016/j.cmet.2015.06.023>
- Nadtochiy, S.M., Schafer, X., Fu, D., Nehrke, K., Munger, J. and Brookes, P.S. (2016) Acidic pH is a metabolic switch for 2-Hydroxyglutarate generation and signaling. *J. Biol. Chem.* **291**, 20188–20197 <https://doi.org/10.1074/jbc.M116.738799>
- Nota, B., Struys, E.A., Pop, A., Jansen, E.E., Fernandez Ojeda, M.R., Kanhai, W.A. et al. (2013) Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. *Am. J. Hum. Genet.* **92**, 627–631 <https://doi.org/10.1016/j.ajhg.2013.03.009>
- Moroni, I., Bugiani, M., D'Incerti, L., Maccagnano, C., Rimoldi, M., Bissola, L. et al. (2004) L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? *Neurology* **62**, 1882–1884 <https://doi.org/10.1212/01.wnl.0000125335.21381.77>

- 22 Jiang, L., Boufersaoui, A., Yang, C., Ko, B., Rakheja, D., Guevara, G. et al. (2017) Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein. *Metab. Eng.* **43**, 198–207 <https://doi.org/10.1016/j.ymben.2016.11.004>
- 23 Bonnet, C., Thomas, L., Psimaras, D., Bielle, F., Vauléon, E., Loiseau, H. et al. (2016) Characteristics of gliomas in patients with somatic IDH mosaicism. *Acta Neuropathol. Commun.* **4**, 31 <https://doi.org/10.1186/s40478-016-0302-y>
- 24 Garraway, L.A. and Lander, E.S. (2013) Lessons from the cancer genome. *Cell* **153**, 17–37 <https://doi.org/10.1016/j.cell.2013.03.002>
- 25 Flavahan, W.A., Drier, Y., Liao, B.B., Gillespie, S.M., Venteicher, A.S., Stemmer-Rachamimov, A. et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. *Nature* **529**, 110–114 <https://doi.org/10.1038/nature16490>
- 26 Sulkowski, P.L., Oeck, S., Dow, J., Economos, N.G., Mirfakhraie, L., Liu, Y. et al. (2020) Oncometabolites suppress DNA repair by disrupting local chromatin signalling. *Nature* **582**, 586–591 <https://doi.org/10.1038/s41586-020-2363-0>
- 27 Stuani, L., Riols, F., Millard, P., Sabatier, M., Batut, A., Saland, E. et al. (2018) Stable isotope labeling highlights enhanced fatty acid and lipid metabolism in human acute myeloid leukemia. *Int. J. Mol. Sci.* **19**, 3325 <https://doi.org/10.3390/ijms19113325>
- 28 Reitman, Z.J., Jin, G., Karoly, E.D., Spasojevic, I., Yang, J., Kinzler, K.W. et al. (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. *Proc. Natl Acad. Sci. U.S.A.* **108**, 3270–3275 <https://doi.org/10.1073/pnas.1019393108>
- 29 Majewski, J. and Ott, J. (2002) Distribution and characterisation of regulatory elements in the human genome. *Genome Res.* **12**, 1827–1836 <https://doi.org/10.1101/gr.606402>
- 30 Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C. and von Deimling, A. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol.* **116**, 597–602 <https://doi.org/10.1007/s00401-008-0455-2>
- 31 Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A. et al. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathol.* **118**, 469–474 <https://doi.org/10.1007/s00401-009-0561-9>
- 32 Ichimura, K., Pearson, D.M., Kocalkowski, S., Bäcklund, L.M., Chan, R., Jones, D.T. et al. (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro Oncol.* **11**, 341–347 <https://doi.org/10.1215/15228517-2009-025>
- 33 Watanabe, T., Nobusawa, S., Kleihues, P. and Ohgaki, H. (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am. J. Pathol.* **174**, 1149–1153 <https://doi.org/10.2353/ajpath.2009.080958>
- 34 Amary, M.F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F. et al. (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J. Pathol.* **224**, 334–343 <https://doi.org/10.1002/path.2913>
- 35 Arai, M., Nobusawa, S., Ikota, S. and Nakazato, Y. (2012) Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. *Brain Tumor Pathol.* **29**, 201–206 <https://doi.org/10.1007/s10014-012-0085-1>
- 36 Lugowska, I., Teterycz, P., Mikula, M., Kulecka, M., Kluska, A., Balabas, A. et al. (2018) IDH1/2 mutations predict shorter survival in chondrosarcoma. *J. Cancer* **9**, 998–1005 <https://doi.org/10.7150/jca.22915>
- 37 Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K. et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. *N. Engl. J. Med.* **361**, 1058–1066 <https://doi.org/10.1056/NEJMoa0903840>
- 38 Abbas, S., Lugthart, S., Kavelaars, F.G., Schelen, A., Koenders, J.E., Zeilemaker, A. et al. (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood* **116**, 2122 <https://doi.org/10.1182/blood-2009-11-250878>
- 39 Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrózek, K., Margeson, D. et al. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. *J. Clin. Oncol.* **28**, 2348–2355 <https://doi.org/10.1200/JCO.2009.27.3730>
- 40 Schnittger, S., Haferlach, C., Ulke, M., Aplerman, T., Kern, W. and Haferlach, T. (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. *Blood* **116**, 5486 <https://doi.org/10.1182/blood-2010-02-267955>
- 41 Wagner, K., Damm, F., Gohring, G., Gorlich, K., Heuser, M., Schafer, I. et al. (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. *J. Clin. Oncol.* **28**, 2356–2364 <https://doi.org/10.1200/JCO.2009.27.6899>
- 42 Kipp, B.R., Voss, J.S., Kerr, S.E., Barr Fritcher, E.G., Graham, R.P., Zhang, L. et al. (2012) Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. *Hum. Pathol.* **43**, 1552–1558 <https://doi.org/10.1016/j.humpath.2011.12.007>
- 43 Wang, P., Dong, Q., Zhang, C., Kuan, P.F., Liu, Y., Jeck, W.R. et al. (2013) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. *Oncogene* **32**, 3091–3100 <https://doi.org/10.1038/onc.2012.315>
- 44 Cairns, R.A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J.P. et al. (2012) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood* **119**, 1901–1903 <https://doi.org/10.1182/blood-2011-11-391748>
- 45 Dogan, S., Chute, D.J., Xu, B., Ptashkin, R.N., Chandramohan, R., Casanova-Murphy, J. et al. (2017) Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. *J. Pathol.* **242**, 400–408 <https://doi.org/10.1002/path.4915>
- 46 Jo, V.Y., Chau, N.G., Hornick, J.L., Hrane, J.F. and Sholl, L.M. (2017) Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma. *Mod. Pathol.* **30**, 650 <https://doi.org/10.1038/modpathol.2016.239>
- 47 Chiang, S., Weigelt, B., Wen, H.C., Pareja, F., Raghavendra, A., Martelotto, L.G. et al. (2016) IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity. *Cancer Res.* **76**, 7118–7129 <https://doi.org/10.1158/0008-5472.CAN-16-0298>
- 48 Lozada, J.R., Basili, T., Pareja, F., Alemar, B., Paula, A., Gularte-Merida, R. et al. (2018) Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. *Histopathology* **73**, 339–344 <https://doi.org/10.1111/his.13522>
- 49 Poetsch, L., Bronnimann, C., Loiseau, H., Frénel, J.S., Siegfried, A., Seizeur, R. et al. (2021) Characteristics of IDH-mutant gliomas with non-canonical IDH mutation. *J. Neurooncol.* **151**, 279–286 <https://doi.org/10.1007/s11060-020-03662-x>

- 50 Kang, M.R., Kim, M.S., Oh, J.E., Kim, Y.R., Song, S.Y., Seo, S.I. et al. (2009) *Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer* **125**, 353–355 <https://doi.org/10.1002/ijc.24379>
- 51 Duchmann, M., Micol, J.B., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J.P. et al. (2021) Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. *Blood* **137**, 2827–2837 <https://doi.org/10.1182/blood.2020010165>
- 52 Thol, F., Weissinger, E.M., Krauter, J., Wagner, K., Damm, F., Wichmann, M. et al. (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. *Haematologica* **95**, 1668–1674 <https://doi.org/10.3324/haematol.2010.025494>
- 53 Rahul, E., Goel, H., Chopra, A., Ranjan, A., Gupta, A.K., Meena, J.P. et al. (2021) An updated account on molecular heterogeneity of acute leukemia. *Am. J. Blood Res.* **11**, 22–43 PMID:33796387
- 54 Wang, C., McKeithan, T.W., Gong, Q., Zhang, W., Bouska, A., Rosenwald, A. et al. (2015) IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. *Blood* **126**, 1741–1752 <https://doi.org/10.1182/blood-2015-05-644591>
- 55 Pardanani, A., Lasho, T.L., Finke, C.M., Mai, M., McClure, R.F. and Tefferi, A. (2010) IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. *Leukemia* **24**, 1146 <https://doi.org/10.1038/leu.2010.77>
- 56 Tefferi, A., Lasho, T.L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D. et al. (2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. *Leukemia* **24**, 1302–1309 <https://doi.org/10.1038/leu.2010.113>
- 57 Oki, K., Takita, J., Hiwatari, M., Nishimura, R., Sanada, M., Okubo, J., et al. (2011) IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. *Leukemia* **25**, 382 <https://doi.org/10.1038/leu.2010.307>
- 58 Andersson, A.K., Miller, D.W., Lynch, J.A., Lemoff, A.S., Cai, Z., Pounds, S.B. et al. (2011) IDH1 and IDH2 mutations in pediatric acute leukemia. *Leukemia* **25**, 1570–1577 <https://doi.org/10.1038/leu.2011.133>
- 59 Borger, D.R., Tanabe, K.K., Fan, K.C., Lopez, H.U., Fantin, V.R., Straley, K.S. et al. (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncologist* **17**, 72–79 <https://doi.org/10.1634/theoncologist.2011-0386>
- 60 Jiao, Y., Pawlik, T.M., Anders, R.A., Selaru, F.M., Streppel, M.M., Lucas, D.J. et al. (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat. Genet.* **45**, 1470–1473 <https://doi.org/10.1038/ng.2813>
- 61 Ross, J.S., Wang, K., Gay, L., Al-Rohil, R., Rand, J.V., Jones, D.M. et al. (2014) New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. *Oncologist* **19**, 235–242 <https://doi.org/10.1634/theoncologist.2013-0352>
- 62 Farshidfar, F., Zheng, S., Gingras, M.C., Newton, Y., Shih, J., Robertson, A.G. et al. (2017) Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. *Cell Rep.* **18**, 2780–2794 <https://doi.org/10.1016/j.celrep.2017.02.033>
- 63 Ally, A., Balasundaram, M., Carlsen, R., Chuah, R., Clarke, A., Dhalla, N. et al. (2017) Comprehensive and integrative genomic characterization of hepatocellular carcinoma. *Cell* **169**, 1327–1341.E23 <https://doi.org/10.1016/j.cell.2017.05.046>
- 64 Lu, C., Venneti, S., Akalin, A., Fang, F., Ward, P.S., Dematteo, R.G. et al. (2013) Induction of sarcomas by mutant IDH2. *Genes Dev.* **27**, 1986–1998 <https://doi.org/10.1101/gad.226753.113>
- 65 Jin, Y., Elalaf, H., Watanabe, M., Tamaki, S., Hinenno, S., Matsunaga, K. et al. (2015) Mutant IDH1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related genes. *PLoS ONE* **10**, e0131998 <https://doi.org/10.1371/journal.pone.0131998>
- 66 Tallegas, M., Miquelostorena-Standley, E., Labit-Bouvier, C., Badoual, C., Francois, A., Gomez-Brouchet, A. et al. (2019) IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract. *Hum. Pathol.* **84**, 183–191 <https://doi.org/10.1016/j.humpath.2018.09.015>
- 67 Zhu, G.G., Nafa, K., Agaram, N., Zehir, A., Benayed, R., Sadowska, J. et al. (2020) Genomic profiling identifies association of IDH1/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma. *Clin. Cancer Res.* **26**, 419–427 <https://doi.org/10.1158/1078-0432.CCR-18-4212>
- 68 Kato Kaneko, M., Liu, X., Oki, H., Ogasawara, S., Nakamura, T., Saidoh, N. et al. (2014) Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. *Cancer Sci.* **105**, 744–748 <https://doi.org/10.1111/cas.12413>
- 69 Liu, X., Kato, Y., Kaneko, M.K., Sugawara, M., Ogasawara, S., Tsujimoto, Y. et al. (2013) Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody msMab-1. *Cancer Med.* **2**, 803–814 <https://doi.org/10.1002/cam4.149>
- 70 Na, K.Y., Noh, B.J., Sung, J.Y., Kim, Y.W., Santini Araujo, E. and Park, Y.K. (2015) IDH mutation analysis in Ewing sarcoma family tumors. *J. Pathol. Transl. Med.* **49**, 257–261 <https://doi.org/10.4132/jptm.2015.04.14>
- 71 Pansuriya, T.C., van Eijk, R., d'Adamo, P., van Ruler, M.A., Kuijjer, M.L., Oosting, J. et al. (2011) Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. *Nat. Genet.* **43**, 1256–1261 <https://doi.org/10.1038/ng.1004>
- 72 Amary, M.F., Damato, S., Halai, D., Eskandarpour, M., Berisha, F., Bonar, F. et al. (2011) Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. *Nat. Genet.* **43**, 1262 <https://doi.org/10.1038/ng.994>
- 73 Fathi, A.T., Sadrzadeh, H., Comander, A.H., Higgins, M.J., Bardia, A., Perry, A. et al. (2014) Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. *Oncologist* **19**, 602–607 <https://doi.org/10.1634/theoncologist.2013-0417>
- 74 Li-Chang, H.H., Kasaian, K., Ng, Y., Lum, A., Kong, E., Lim, H. et al. (2015) Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. *BMC Cancer* **15**, 32 <https://doi.org/10.1186/s12885-015-1021-7>
- 75 Hartman, D.J., Binon, D., Regueiro, M., Schraut, W., Bahary, N., Sun, W. et al. (2014) Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma. *Am. J. Surg. Pathol.* **38**, 1147–1156 <https://doi.org/10.1097/PAS.0000000000000239>
- 76 Lopez, G.Y., Reitman, Z.J., Solomon, D., Waldman, T., Bigner, D.D., McLendon, R.E. et al. (2010) IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. *Biochem. Biophys. Res. Commun.* **398**, 585–587 <https://doi.org/10.1016/j.bbrc.2010.06.125>
- 77 Toth, L.N., de Abreu, F.B. and Tafe, L.J. (2018) Non–small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. *Hum. Pathol.* **78**, 138–143 <https://doi.org/10.1016/j.humpath.2018.04.014>

- 78 Gaal, J., Burnichon, N., Korpershoek, E., Roncailin, I., Bertherat, J., Plouin, P.F. et al. (2010) Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. *J. Clin. Endocrinol. Metab.* **95**, 1274–1278 <https://doi.org/10.1210/jc.2009-2170>
- 79 Hinsch, A., Brolund, M., Hube-Magg, C., Kluth, M., Somin, R., Moller-Koop, C. et al. (2018) Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. *World J. Urol.* **36**, 877–882 <https://doi.org/10.1007/s00345-018-2225-7>
- 80 Riobello, C., Lopez-Hernandez, A., Cabai, V., Garcia-Marin, R., Suarez-Fernandez, L., Suarez-Fernandes, P. et al. (2020) IDH2 mutation analysis in undifferentiated and poorly differentiated sinonasal carcinomas for diagnosis and clinical management. *Am. J. Surg. Pathol.* **44**, 396–405 <https://doi.org/10.1097/PAS.0000000000001420>
- 81 Kurek, K.C., Pansuriya, T.C., van Ruler, M.A.J.H., van den Akker, B., Luks, V.L., Verbeke, S.L.J. et al. (2013) R132c IDH1 mutations Are found in spindle cell hemangiomas and Not in other vascular tumors or malformations. *Am. J. Pathol.* **182**, 1494–1500 <https://doi.org/10.1016/j.ajpath.2013.01.012>
- 82 Murugan, A.K., Bojdani, E. and Xing, M. (2010) Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. *Biochem. Biophys. Res. Commun.* **393**, 555–559 <https://doi.org/10.1016/j.bbrc.2010.02.095>
- 83 Hemeryly, J.P., Bastos, A.U. and Cerutti, J.M. (2010) Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. *Eur. J. Endocrinol.* **163**, 747 <https://doi.org/10.1530/EJE-10-0473>
- 84 Rakheja, D., Mitui, M., Boriack, R.L. and DeBerardinis, R.J. (2011) Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in wilms tumors. *Pediatr. Blood Cancer* **56**, 379–383 <https://doi.org/10.1002/pbc.22697>
- 85 Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R. et al. (2004) A census of human cancer genes. *Nat. Rev. Cancer* **4**, 177–183 <https://doi.org/10.1038/nrc1299>
- 86 McGraw, K.L., Cheng, C.H., Chen, Y.A., Hou, H.A., Nilsson, B., Genovese, G. et al. (2019) Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. *Blood Adv.* **3**, 3579–3589 <https://doi.org/10.1182/bloodadvances.201900092>
- 87 Villafranca, J.J. and Colman, R.F. (1972) Role of metal ions in reactions catalyzed by pig heart triphosphopyridine nucleotide-dependent isocitrate dehydrogenase. *J. Biol. Chem.* **247**, 215–223 [https://doi.org/10.1016/S0021-9258\(19\)45778-5](https://doi.org/10.1016/S0021-9258(19)45778-5)
- 88 Roman, J.V., Melkonian, T.R., Silvaggi, N.R. and Moran, G.R. (2019) Transient-state analysis of human isocitrate dehydrogenase I: accounting for the interconversion of active and non-active conformational states. *Biochemistry* **58**, 5366–5380 <https://doi.org/10.1021/acs.biochem.9b00518>
- 89 Taylor, J.S., Vigneron, D.B., Murphy-Boesch, J., Nelson, S.J., Kessler, H.B., Coia, L. et al. (1991) Free magnesium levels in normal human brain and brain tumors: ³¹P chemical-shift imaging measurements at 1.5T. *Proc. Natl Acad. Sci. U.S.A.* **88**, 6810–6814 <https://doi.org/10.1073/pnas.88.15.6810>
- 90 Romani, A.M.P. (2011) Cellular magnesium homeostasis. *Arch. Biochem. Biophys.* **512**, 1–23 <https://doi.org/10.1016/j.abb.2011.05.010>
- 91 Ducret, T., Boudina, S., Sorin, B., Vacher, A.M., Gourdou, I., Liguoro, D. et al. (2002) Effects of prolactin on intracellular calcium concentration and cell proliferation in human glioma cells. *Glia* **38**, 200–214 <https://doi.org/10.1002/glia.10056>
- 92 Luna, L.A., Lesecq, Z., White, K.A., Hoang, A., Scott, D.A., Zagnitko, O. et al. (2020) An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity. *Biochem. J.* **477**, 2999–3018 <https://doi.org/10.1042/BCJ20200311>
- 93 Hugg, J.W., Matson, G.B., Twieg, D.B., Maudsley, A.A., Sappey-Mariniere, D. and Weiner, M.W. (1992) Phosphorus-31 MR spectroscopic imaging (MRSI) of normal and pathological human brains. *Magn. Reson. Imaging* **10**, 227–243 [https://doi.org/10.1016/0730-725x\(92\)9048](https://doi.org/10.1016/0730-725x(92)9048)
- 94 Golub, D., Iyengar, N., Dogra, S., Wong, T., Bready, D., Tang, K. et al. (2019) Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. *Front. Oncol.* **9**, 417 <https://doi.org/10.3389/fonc.2019.00417>
- 95 Pusch, S., Krausert, S., Fischer, V., Balss, J., Ott, M., Schrimpf, D. et al. (2017) Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma *in vivo*. *Acta Neuropathol.* **133**, 629–644 <https://doi.org/10.1007/s00401-017-1677-y>
- 96 Okoye-Okafor, U.C., Bartholdy, B., Cartier, J., Gao, E.N., Pietrak, B., Rendina, A.R. et al. (2015) New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. *Nat. Chem. Biol.* **11**, 878–886 <https://doi.org/10.1038/nchembio.1930>
- 97 Cho, Y.S., Levell, J.R., Liu, G., Caferro, T., Sutton, J., Shafer, C.M. et al. (2017) Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor. *ACS Med. Chem. Lett.* **8**, 1116–1121 <https://doi.org/10.1021/acsmedchemlett.7b00342>
- 98 Davis, M., Prangani, R., Popovici-Muller, J., Gross, S., Thorne, N., Salituro, F. et al. (2012). ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. In *Probe Reports From the NIH Molecular Libraries Program [Internet]*. Bethesda (MD): National Center for Biotechnology Information (US); 2010. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK153220/>
- 99 Xie, X., Baird, D., Bowen, K., Capka, V., Chen, J., Chenail, G. et al. (2017) Allosteric mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity. *Structure* **25**, 506–513 <https://doi.org/10.1016/j.str.2016.12.017>
- 100 A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation. [March 2021 Active; not recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT03684811>
- 101 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation. August 2019; recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT03683433>
- 102 IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation. [October 2020; recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT03564821>
- 103 IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation. [May 2021, active, not recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT03515512>
- 104 Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies. [May 2021; recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT03471260>
- 105 Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome. Available from: [January 2021; recruiting] <https://ClinicalTrials.gov/show/NCT03383575>
- 106 Study of AG-120 and AG-881 in Subjects With Low Grade Glioma. [May 2021: active not recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT03343197>
- 107 BAY1436032 in Patients With Mutant IDH1 (mIDH1) Advanced Acute Myeloid Leukemia (AML). [May 2019: completed]; Available from: <https://ClinicalTrials.gov/show/NCT03127735>
- 108 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma. [December 2017: withdrawn]; Available from: <https://ClinicalTrials.gov/show/NCT02977689>

- 109 Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors. [May 2021: Active not recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT02746081>
- 110 A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML). [December 2019 Active not recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT02677922>
- 111 Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. [June 2021: Active not recruiting]; Available from: <https://ClinicalTrials.gov/show/NCT02073994>
- 112 Amatangelo, M.D., Quek, L., Shih, A., Stein, E.M., Roshal, M., David, M.D. et al. (2017) Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. *Blood* **130**, 732–741 <https://doi.org/10.1182/blood-2017-04-779447>
- 113 Suijker, J., Oosting, J., Koornneef, A., Struys, E.A., Salomons, G.S., Schaap, F.G. et al. (2015) Inhibition of mutant IDH1 decreases D-2HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. *Oncotarget* **6**, 12505–12519 <https://doi.org/10.18632/oncotarget.3723>
- 114 Roboz, G.J., DiNardo, C.D., Stein, E.M., de Botton, S., Mims, A.S., Prince, G.T. et al. (2020) Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. *Blood* **135**, 463–471 <https://doi.org/10.1182/blood.2019002140>
- 115 Stein, E.M., DiNardo, C.D., Pollyea, D.A., Fathi, A.T., Roboz, G.J., Altman, J.K. et al. (2017) Enasidenib in mutant *IDH2* relapsed or refractory acute myeloid leukemia. *Blood* **130**, 722–731 <https://doi.org/10.1182/blood-2017-04-779405>
- 116 Pollyea D, A., Tallman M, S., de Botton, S., Kantarjian, H.M., Collins, R., Stein, A.S. et al. (2019) Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. *Leukemia* **33**, 2575–2584 <https://doi.org/10.1038/s41375-019-0472-2>
- 117 Intlekofer, A.M., Shih, A.H., Wang, B., Nazir, A., Rustenburg, A.S., Albanese, S.K. et al. (2018) Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. *Nature* **559**, 125–129 <https://doi.org/10.1038/s41586-018-0251-7>
- 118 Harding, J.J., Lowery, M.A., Shih, A.H., Schwartzman, J.M., Hou, S., Famulare, C. et al. (2018) Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. *Cancer Discov.* **8**, 1540–1547 <https://doi.org/10.1158/2159-8290.CD-18-0877>
- 119 Choe, S., Wang, H., DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J. et al. (2020) Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. *Blood Adv.* **4**, 1894–1905 <https://doi.org/10.1182/bloodadvances.2020001503>
- 120 Avellaneda Matteo, D., Wells, G.A., Luna, L.A., Grunseth, A.J., Zagnitko, O., Scott, D.A. et al. (2018) Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. *Biochem. J.* **475**, 3221–3238 <https://doi.org/10.1042/BCJ20180424>
- 121 CB-839 With Radiation Therapy and Temozolomide in Treating Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma. April 24 2020 [June 2021: recruiting]; Available from: <https://clinicaltrials.gov/ct2/show/NCT03528642>
- 122 Molenaar, R.J., Thota, S., Nagata, Y., Patel, B., Clemente, M., Przychodzen, B. et al. (2015) Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. *Leukemia* **29**, 2134–2142 <https://doi.org/10.1038/leu.2015.91>
- 123 Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A. et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* **18**, 553–567 <https://doi.org/10.1016/j.ccr.2010.11.015>
- 124 Paschka, P., Schlenk, R.F., Gaidzik, V., Habdank, M., Kronke, J., Bullinger, L. et al. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia With NPM1 mutation without FLT3 internal tandem duplication. *J. Clin. Oncol.* **28**, 3636–3643 <https://doi.org/10.1200/JCO.2010.28.3762>